OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000898437

Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics, Inc. (CIK 0000898437, ticker ANIK, EIN 04-3145961) reported revenue of $112.82 million ($112,819,000) for FY2025 (2025-01-01 to 2025-12-31) and net income of -$10.88 million (-$10,880,000) for FY2025 (2025-01-01 to 2025-12-31), as filed in its 10-K filed 2026-03-03 (accession 0001171843-26-001275).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000898437
TickersANIK (Nasdaq)
EIN04-3145961
SIC industry code3841 Surgical & Medical Instruments & Apparatus
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryAccelerated filer
Entity typeoperating
Olympus entity IDorg_53aa1fkp2yk4trhxv5b8r0hyg7
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$112,819,000FY20252025-01-01 to 2025-12-3110-K2026-03-030001171843-26-001275RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$10,880,000FY20252025-01-01 to 2025-12-3110-K2026-03-030001171843-26-001275NetIncomeLoss
Total assets$190,270,000FY2025as of 2025-12-3110-K2026-03-030001171843-26-001275Assets
Stockholders' equity$143,465,000FY2025as of 2025-12-3110-K2026-03-030001171843-26-001275StockholdersEquity
Operating cash flow$11,188,000FY20252025-01-01 to 2025-12-3110-K2026-03-030001171843-26-001275NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.76 per shareFY20252025-01-01 to 2025-12-3110-K2026-03-030001171843-26-001275EarningsPerShareDiluted
Shares outstanding13,400,751 sharesFY2025as of 2026-02-2010-K2026-03-030001171843-26-001275EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20252025-01-01 to 2025-12-31$112,819,00010-K2026-03-030001171843-26-001275
RevenueFY20242024-01-01 to 2024-12-31$119,907,00010-K2026-03-030001171843-26-001275
RevenueFY20232023-01-01 to 2023-12-31$120,792,00010-K2026-03-030001171843-26-001275
RevenueFY20222022-01-01 to 2022-12-31$113,827,00010-K2025-03-170001171843-25-001486
RevenueFY20212021-01-01 to 2021-12-31$147,794,00010-K2024-03-150001171843-24-001380
RevenueFY20202020-01-01 to 2020-12-31$130,457,00010-K2023-03-160001171843-23-001729
RevenueFY20192019-01-01 to 2019-12-31$114,610,00010-K2022-03-110001171843-22-001790
RevenueFY20182018-01-01 to 2018-12-31$105,555,00010-K/A2021-04-260001171843-21-002766
RevenueFY20172017-01-01 to 2017-12-31$113,420,00010-K2020-03-060001171843-20-001536
RevenueFY20162016-01-01 to 2016-12-31$103,379,00010-K2019-02-270001171843-19-001243
Net incomeFY20252025-01-01 to 2025-12-31-$10,880,00010-K2026-03-030001171843-26-001275
Net incomeFY20242024-01-01 to 2024-12-31-$56,385,00010-K2026-03-030001171843-26-001275
Net incomeFY20232023-01-01 to 2023-12-31-$82,667,00010-K2026-03-030001171843-26-001275
Net incomeFY20222022-01-01 to 2022-12-31-$14,859,00010-K2025-03-170001171843-25-001486
Net incomeFY20212021-01-01 to 2021-12-31$4,134,00010-K2024-03-150001171843-24-001380
Net incomeFY20202020-01-01 to 2020-12-31-$23,982,00010-K2023-03-160001171843-23-001729
Net incomeFY20192019-01-01 to 2019-12-31$27,193,00010-K2022-03-110001171843-22-001790
Net incomeFY20182018-01-01 to 2018-12-31$18,722,00010-K/A2021-04-260001171843-21-002766
Net incomeFY20172017-01-01 to 2017-12-31$31,816,00010-K2020-03-060001171843-20-001536
Net incomeFY20162016-01-01 to 2016-12-31$32,547,00010-K2019-02-270001171843-19-001243
  • Revenue for FY2023 was restated: first reported as $166,662,000 (accession 0001171843-24-001380, filed 2024-03-15).
  • Revenue for FY2022 was restated: first reported as $156,236,000 (accession 0001171843-23-001729, filed 2023-03-16).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-07-292026-06-300001171843-26-005012anik20260630_10q.htm
10-Q2026-04-302026-03-310001171843-26-002852anik20260331_10q.htm
10-K2026-03-032025-12-310001171843-26-001275anik20251231_10k.htm
10-Q2025-11-052025-09-300001171843-25-007032anik20250930_10q.htm
10-Q2025-07-302025-06-300001171843-25-004826anik20250630_10q.htm
10-Q2025-05-092025-03-310001171843-25-003019anik20250331_10q.htm
10-K2025-03-172024-12-310001171843-25-001486anik20241231_10k.htm
10-Q2024-11-042024-09-300001171843-24-005993anik20240930_10q.htm
10-Q2024-08-082024-06-300001171843-24-004615anik20240630_10q.htm
10-Q2024-05-082024-03-310001171843-24-002682anik20240331c_10q.htm
10-K/A2024-04-262023-12-310001171843-24-002274anik20231231_10ka.htm
10-K2024-03-152023-12-310001171843-24-001380anik20231231_10k.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000898437published by the sourcedata.sec.gov/submissions/CIK0000898437.json2026-10-21
Employer Identification Number (EIN) · US-EIN04-3145961published by the sourceaskebsa.dol.gov/FOIA%20Files/2024/Latest/F_5500_2024_Latest.zip2026-10-22
Employer Identification Number (EIN) · US-EIN04-3145961published by the sourcedata.sec.gov/submissions/CIK0000898437.json2026-10-21

Same entity in other Olympus APIs

Records other Olympus APIs serve for this entity, linked through a published identifier (never matched on name).

APIRecordAPI pathLinked through
US Employee Benefits & Form 5500 APIsponsor/v1/form-5500/sponsors/043145961US-EIN 043145961

Former names

NameFromTo
ANIKA THERAPEUTICS INC1997-05-152014-03-13
ANIKA RESEARCH INC1996-07-241996-11-27

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000898437.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000898437.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000898437" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000898437/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000898437/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"898437"}

On SEC EDGAR

About this data